Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Mobile App Data Provided for Chronic Pain Study

Manage My Pain app home screen (Google Play)

21 May 2015. Data collected by a mobile app designed to help individuals manage their pain are being provided to a research lab at York University to reveal patterns in painful experiences by the app’s users. York’s Human Pain Mechanisms Lab in Toronto, Ontario, Canada . . . → Read More: Mobile App Data Provided for Chronic Pain Study

Orphan Status Granted Eye Cancer Treatment

(Public Domain Pictures, Pixabay)

21 May 2015. Food and Drug Administration designated an experimental treatment for uveal melanoma, a rare and aggressive form of cancer in the eye, as an orphan drug that qualifies for incentives to expedite its development. Aura Biosciences also revealed results of preclinical tests showing the ability of its . . . → Read More: Orphan Status Granted Eye Cancer Treatment

Phillips, MIT Form Health Technology Collaboration

Henk van Houten, head of Philips Research, left, and MIT Associate Provost Karen Gleason at signing of research collaboration agreement (Dominick Reuter, Massachusetts Institute of Technology)

20 May 2015. Electronics manufacturer Royal Phillips and Massachusetts Institute of Technology are collaborating on research into health care technology and digital urban lighting systems. The 5-year, . . . → Read More: Phillips, MIT Form Health Technology Collaboration

FDA Approves Four-Times-Per-Year Schizophrenia Drug

(Allan Ajifo, Wikimedia Commons)

19 May 2015. Food and Drug Administration approved for sale in the U.S. a drug for controlling schizophrenia symptoms that individuals need to take only four times per year. Janssen Pharmaceuticals, a division of Johnson & Johnson, markets the three-month version of the drug paliperidone palmitate under the brand . . . → Read More: FDA Approves Four-Times-Per-Year Schizophrenia Drug

Lab-On-Chip Device Captures Circulating Tumor Cells

Fluorescent tagged tumor cell cluster captured in a Cluster-Chip (Mehmet Toner, Massachusetts General Hospital)

19 May 2015. Engineers and medical researchers designed a microchip that detects clusters of circulating tumor cells that break away from tumors and can spread cancer throughout the body. The team from a joint Harvard-MIT health sciences technology program . . . → Read More: Lab-On-Chip Device Captures Circulating Tumor Cells

National Academies to Develop Gene-Editing Guidelines

Artist depiction of Cas9 protein editing a gene (Jennifer Doudna, University of California – Berkeley)

18 May 2015. National Academy of Sciences and Institute of Medicine plan to write guidelines governing an emerging technology for editing human genomes. The initiative includes an international meeting in the fall to discuss the scientific, ethical, and . . . → Read More: National Academies to Develop Gene-Editing Guidelines

AstraZeneca Building New Biologics Plant

AstraZeneca laboratory in Södertälje, Sweden (AstraZeneca)

18 May 2015. The pharmaceutical company AstraZeneca plans to build a new facility in Södertälje, Sweden to manufacture biologic medications. The $285 million plant is expected to employ from 150 to 250 workers when it goes into operation in 2019.

Södertälje is the site of AstraZeneca’s largest . . . → Read More: AstraZeneca Building New Biologics Plant

Trial Shows Antibody Reduces Days with Migraines

(R. Nial Bradshaw, Flickr)

15 May 2015. A clinical trial shows high doses of an engineered antibody reduced the number of days per month that people with a history of migraines experience migraine episodes. First findings from the intermediate-stage trial of the antibody code-named AMG334 by the biotechnology company Amgen were reported at . . . → Read More: Trial Shows Antibody Reduces Days with Migraines

Oxford Establishes £300M Spin-Off Capital Fund

MinIon handheld sequencing device (Oxford Nanopore Technologies)

15 May 2015. University of Oxford in the U.K. is creating a capital investment fund to help launch spin-off companies based on research from university labs. The £300 million ($US 472 million) fund will be managed by a new enterprise, Oxford Sciences Innovation plc, which will . . . → Read More: Oxford Establishes £300M Spin-Off Capital Fund

Sanford-Burnham, Lilly Partnering on Immune Therapies

Scanning electron micrograph of a human T-cell lymphocyte (National Institute of Allergy and Infectious Diseases, NIH)

14 May 2015. Sanford-Burnham Research Institute and Eli Lilly and Company are collaborating on discovering new therapies for immune system disorders using biotechnology tools. Financial and intellectual property aspects of their agreement were not disclosed.

The partnership . . . → Read More: Sanford-Burnham, Lilly Partnering on Immune Therapies